Compare · AGL vs LSTA
AGL vs LSTA
Side-by-side comparison of agilon health inc. (AGL) and Lisata Therapeutics Inc. (LSTA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AGL and LSTA operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- AGL is the larger of the two at $435.2M, about 15.1x LSTA ($28.9M).
- Over the past year, AGL is down 72.9% and LSTA is up 31.6% - LSTA leads by 104.5 points.
- AGL has been more active in the news (7 items in the past 4 weeks vs 2 for LSTA).
- AGL has more recent analyst coverage (25 ratings vs 0 for LSTA).
PerformanceAGL-72.94%LSTA+31.56%
2025-04-28+0.00%2026-04-24
- Company
- agilon health inc.
- Lisata Therapeutics Inc.
- Price
- $26.01-0.80%
- $3.21-3.89%
- Market cap
- $435.2M
- $28.9M
- 1M return
- +143.08%
- -36.12%
- 1Y return
- -72.94%
- +31.56%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 7
- 2
- Recent ratings
- 25
- 0
AGL
agilon health inc.
agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. The company was founded in 2016 and is based in Long Beach, California.
Latest AGL
- SEC Form DEFA14A filed by agilon health inc.
- SEC Form DEF 14A filed by agilon health inc.
- SEC Form 4 filed by Zamore Denise
- SEC Form 4 filed by Venkatachaliah Girish
- SEC Form 4 filed by Gertsch Timothy
- SEC Form 4 filed by Shaker Benjamin
- agilon health Sets Date to Report First Quarter 2026 Financial Results
- SEC Form 4 filed by Schwaneke Jeffrey A.
- SEC Form 4 filed by Shaker Benjamin
- SEC Form 4 filed by Gertsch Timothy
Latest LSTA
- SEC Form SC14D9C filed by Lisata Therapeutics Inc.
- SEC Form 8-K filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SEC Form SC14D9C filed by Lisata Therapeutics Inc.
- SEC Form 10-K filed by Lisata Therapeutics Inc.
- SEC Form SC14D9C filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure
- Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
- SEC Form SC14D9C filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement